Copertura documentale

Il Quality Gate pubblico registra 10 supporti documentali, 4 fonti indipendenti e 6 relazioni. Questi valori misurano documentazione e provenienza, non efficacia o appropriatezza clinica.

Documenti indicizzati collegati

• Cost-effectiveness analysis of capivasertib plus fulvestrant in the PIK3CA/AKT1/PTEN-altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective. — PubMed / NCBI
• Early-onset, treatment-cycle-linked hyperinsulinaemic insulin resistance during capivasertib therapy: a case report. — Europe PMC
• Early-onset, treatment-cycle-linked hyperinsulinaemic insulin resistance during capivasertib therapy: a case report. — PubMed / NCBI
• Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients — ClinicalTrials.gov
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) — ClinicalTrials.gov
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) — ClinicalTrials.gov
• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian — ClinicalTrials.gov
• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer — ClinicalTrials.gov
• Comparative efficacy and safety of novel agents versus standard chemotherapy in first-line (1L) locally advanced or metastatic triple-negative breast cancer (TNBC): A systematic review and network meta-analyses. — Crossref
• Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer. — Europe PMC
• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC — ClinicalTrials.gov
• Capivasertib in advanced hormone receptor-positive breast cancer — Crossref

Collegamenti nel Knowledge Graph

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) — uses intervention
• Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients — uses intervention
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) — uses intervention
• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian — uses intervention
• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC — uses intervention
• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer — uses intervention

Come interpretare questa pagina

Una relazione documentale non equivale a una raccomandazione. Risultati favorevoli nelle condizioni studiate, non favorevoli nelle condizioni studiate, non concordanti o con dati insufficienti restano consultabili nel motore con la loro provenienza.

Privacy

Questa pagina deriva esclusivamente dal patrimonio scientifico pubblico indicizzato. Il Publisher non usa IP, cookie, account, cronologia, fingerprint o ricerche individuali.

Quality Gate documentale: 92/100 · ultimo aggiornamento Settembre 29, 2026